From HandWiki - Reading time: 4 min
Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer.[1] It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).[2]
In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy.[3][4]
In December 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Aumseqa, intended for the treatment of non-small cell lung cancer (NSCLC).[5] The applicant for this medicinal product is SFL Pharmaceuticals Deutschland GmbH.[5]